Correction: Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises.
Rebecca Harding, Neomi Singer, Matthew B. Wall, Talma Hendler, David Erritzøe, David Nutt, Robin Carhart-Harris, Leor Roseman
Mol Psychiatry July 1, 2025 correction DOI: 10.1038/s41380-025-03066-1 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial |
|---|---|
| Topics | Psilocybin Psychedelic-assisted therapy Depression |
| Keywords | Depression treatment Mood improvement Mental health therapy Psychiatric treatment Therapeutic mechanisms Relief from depression Brain activity Brain processing Cognitive neuroscience Neural mechanisms Brain function Neurological study Psilocybin research Psilocybin effects Drug study Pharmacological research Escitalopram study Antidepressant research Auditory processing Musical cognition Musical surprises Unexpected events processing Sensory processing Auditory perception Musical note |
| Key findings | Psilocybin therapy decreased activation in the ventromedial prefrontal cortex and angular gyrus while increasing activation in sensory regions during processing of unexpected musical notes. |
Abstract
The following part of the abstract had a minor error: ‘Following PT, there was greater activation in the ventromedial prefrontal cortex and sensory regions, and reduced activation in the angular gyrus.’ This is now corrected to ‘Following PT, there was decreased activation in the ventromedial prefrontal cortex and angular gyrus, and greater activation in sensory regions.’ The original article has been updated accordingly.
Comparable studies
Other randomized controlled trials on psilocybin and psychedelic-assisted therapy, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Healthy adults, mostly hallucinogen-naïve | 2011 | Randomized controlled trial | n = 18 |
| Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder Adults aged 25–65 with DSM-IV alcohol dependence and at least 4 heavy drinking days in... | 2022 | Randomized controlled trial | n = 95 |
| Increased global integration in the brain after psilocybin therapy for depression. Patients with treatment-resistant depression and patients with major depressive disorder | 2022 | Open-label trial and double-blind phase II randomized controlled trial | |
| Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. Adults diagnosed with major depressive disorder and no unstable somatic conditions | 2023 | Double-blind, randomised clinical trial | n = 52 |
| Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin Healthy participants | 2012 | Randomized controlled trial | n = 10 |